101 related articles for article (PubMed ID: 31177140)
21. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic factors and efficacy of molecular targeted therapy for metastatic clear cell renal cell carcinoma].
Inoue R; Kitamura H; Shindo T; Yanase M; Takahashi A; Miyao N; Ito N; Hotta H; Hirose T; Taguchi K; Matsukawa M; Uehara T; Kunishima Y; Hotta H; Masumori N
Hinyokika Kiyo; 2015 Apr; 61(4):135-9. PubMed ID: 26037671
[TBL] [Abstract][Full Text] [Related]
23. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
[TBL] [Abstract][Full Text] [Related]
25. Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kyriakopoulos CE; Chittoria N; Choueiri TK; Kroeger N; Lee JL; Srinivas S; Knox JJ; Bjarnason GA; Ernst SD; Wood LA; Vaishampayan UN; Agarwal N; Pal SK; Kanesvaran R; Rha SY; Yuasa T; Donskov F; North SA; Heng DY; Rini BI
Clin Genitourin Cancer; 2015 Apr; 13(2):e79-85. PubMed ID: 25450036
[TBL] [Abstract][Full Text] [Related]
26. Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment.
Kammerer-Jacquet SF; Brunot A; Bensalah K; Campillo-Gimenez B; Lefort M; Bayat S; Ravaud A; Dupuis F; Yacoub M; Verhoest G; Peyronnet B; Mathieu R; Lespagnol A; Mosser J; Edeline J; Laguerre B; Bernhard JC; Rioux-Leclercq N
Urol Oncol; 2017 Oct; 35(10):603.e7-603.e14. PubMed ID: 28619630
[TBL] [Abstract][Full Text] [Related]
27. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control.
Sheehan JP; Sun MH; Kondziolka D; Flickinger J; Lunsford LD
J Neurosurg; 2003 Feb; 98(2):342-9. PubMed ID: 12593621
[TBL] [Abstract][Full Text] [Related]
28. Results of the whole-brain radiotherapy for patients with brain metastases from lung cancer: the RTOG RPA intra-classes analysis.
Kepka L; Cieslak E; Bujko K; Fijuth J; Wierzchowski M
Acta Oncol; 2005; 44(4):389-98. PubMed ID: 16120548
[TBL] [Abstract][Full Text] [Related]
29. Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma.
You D; Lee C; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2331-8. PubMed ID: 27553579
[TBL] [Abstract][Full Text] [Related]
30. A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy.
Kim SH; Kim S; Joo J; Seo HK; Joung JY; Lee KH; Chung J
BMC Cancer; 2016 Aug; 16():577. PubMed ID: 27484254
[TBL] [Abstract][Full Text] [Related]
31. Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor.
Grassi P; Verzoni E; Porcu L; Testa I; Iacovelli R; Torri V; Braud Fd; Procopio G
Future Oncol; 2014 Jun; 10(8):1361-72. PubMed ID: 25052747
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs.
Lee CH; Hötker AM; Voss MH; Feldman DR; Woo KM; Patil S; Coskey DT; Akin O; Hsieh JJ; Motzer RJ
Clin Genitourin Cancer; 2016 Feb; 14(1):56-62. PubMed ID: 26404107
[TBL] [Abstract][Full Text] [Related]
33. Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era.
Gravis G; Chanez B; Derosa L; Beuselinck B; Barthelemy P; Laguerre B; Brachet PE; Joly F; Escudier B; Harrison DJ; Laird A; Vasudev N; Ralph C; Larkin J; Lote H; Salem N; Walz J; Thomassin J; Sfumato P; Stewart GD; Boher JM;
Urol Oncol; 2016 Apr; 34(4):167.e17-23. PubMed ID: 26670200
[TBL] [Abstract][Full Text] [Related]
34. Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?
Vanhuyse M; Penel N; Caty A; Fumagalli I; Alt M; Zini L; Adenis A
Bull Cancer; 2012 Dec; 99(12):100-6. PubMed ID: 23220100
[TBL] [Abstract][Full Text] [Related]
35. Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center.
Grassi P; Verzoni E; Mariani L; De Braud F; Coppa J; Mazzaferro V; Procopio G
Clin Genitourin Cancer; 2013 Dec; 11(4):484-8. PubMed ID: 23791435
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.
Kang M; Yu J; Sung HH; Jeon HG; Jeong BC; Park SH; Jeon SS; Lee HM; Choi HY; Seo SI
Int J Urol; 2018 Jun; 25(6):596-603. PubMed ID: 29756394
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
[TBL] [Abstract][Full Text] [Related]
38. Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma.
Du Y; Pahernik S; Hadaschik B; Teber D; Duensing S; Jäger D; Hohenfellner M; Grüllich C
J Neurooncol; 2016 Oct; 130(1):221-228. PubMed ID: 27538910
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Factors for Survival of Patients With Synchronous or Metachronous Brain Metastasis of Renal Cell Carcinoma.
Choi SY; Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
Clin Genitourin Cancer; 2017 Dec; 15(6):717-723. PubMed ID: 28552571
[TBL] [Abstract][Full Text] [Related]
40. Institutional, retrospective analysis of 777 patients with brain metastases: treatment outcomes and diagnosis-specific prognostic factors.
Antoni D; Clavier JB; Pop M; Schumacher C; Lefebvre F; Noël G
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):630-7. PubMed ID: 23582409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]